Commercial Credit Report for MediGene AG

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for MediGene AG is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	MediGene AG
Lochhamer Strasse 11
Phone: +49 892000330p:+49 892000330	PLANEGG, 82152 Germany	Ticker: MDG1MDG1

Business Summary

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.

(Source: 10-K405)

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	Yes	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
12/31/2023	12/31/2023	Yes	-	-	-	-

Industries

SIC Code	Description
8731	Commercial physical and biological research

Officers and Directors

Title	Name	Age	Title Date	Start Date
Independent Chairman of the Supervisory Board	GerdZettlmeissl	69	5/23/2019	5/24/2017
Chairman of the Management Board, Chief Executive Officer	SelwynHo	52	7/25/2022	7/25/2022
Independent Deputy Chairman of the Supervisory Board	AntoinetteHiebeler-Hasner	64	8/11/2016	8/11/2016
4 additional Officers and Directors records available in full report.

Business Names

Business Name
Avidex Ltd.
MDG
MDG1
MediGene AG
MedigeneImmunotherapies GmbH
Trianta Immunotherapies GmbH

General Information

Number of Employees:	86	(As of 12/31/2023)
Outstanding Shares:	24,562,658	(As of 12/31/2023)
Shareholders:	50
Stock Exchange:	ETR
Fax Number:	+49 892000332920

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN